How does minimal residual disease (MRD) testing affect treatment decisions? (https://www.myeloma.org/videos/how-does-minimal-residual-disease-mrd-testing-affect-treatment-decisions)
|
In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next steps in a myeloma patient’s treatment. BOTTOM LINE:
|
|||
|
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected] (mailto:[email protected]). To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected] (mailto:[email protected]). |
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.